Taylor Sandison - Cidara Therapeutics Acting Chief Medical Officer
| CDTX Stock | USD 20.21 0.01 0.05% |
Executive
Dr. Taylor Sandison, M.D., M.P.H., was appointed as Chief Medical Officer of the Company. Dr. Sandison was with Cidara since October 2015. Prior to joining the company, he served as senior medical director at Cubist Pharmaceuticals, Inc. from July 2014 to January 2015 and then, following Merck acquisition of Cubist, as senior medical director at Merck from February to October 2015. Dr. Sandison has also held positions at Trius Therapeutics and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, and M.D. and M.P.H. degrees from the University of Washington. He completed residency training at the University of Colorado and fellowship training at the University of Washington. Dr. Sandison holds board certifications in Infectious Diseases and Internal Medicine. since 2017.
| Age | 52 |
| Tenure | 7 years |
| Address | 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 |
| Phone | 858 752 6170 |
| Web | https://www.cidara.com |
Latest Insider Transactions
Cidara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5339) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cidara Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 2.93 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 6.5 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 767 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anne DVM | Molecular Partners AG | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Matteo MD | Cue Biopharma | 55 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| David MBA | Inhibrx | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| MD MBA | Molecular Partners AG | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Bonne MBA | Inhibrx | 47 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Brendan Eckelman | Inhibrx | 45 | |
| Charbel PharmD | Inhibrx | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
Management Performance
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 |
Cidara Therapeutics Leadership Team
Elected by the shareholders, the Cidara Therapeutics' board of directors comprises two types of representatives: Cidara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cidara. The board's role is to monitor Cidara Therapeutics' management team and ensure that shareholders' interests are well served. Cidara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cidara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carol Waldo, VP Assurance | ||
| Preetam MBA, CFO Officer | ||
| James Balkovec, VP Research | ||
| Jeffrey Stein, Chief Executive and President and Executive Director | ||
| Taylor Sandison, Acting Chief Medical Officer | ||
| SPHR CCP, Senior Culture | ||
| Jim MBA, Chief Officer | ||
| Kevin Forrest, Founder, CFO, COO and Treasurer | ||
| Laura Navalta, Senior Vice President - Clinical Operations | ||
| Shane Ward, COO Secretary | ||
| Leslie Tari, Chief Officer | ||
| Les Tari, Vice President - Discovery Research | ||
| MD JD, Senior Development | ||
| MPH MD, Chief Officer |
Cidara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cidara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (36.76) % | ||||
| Current Valuation | 97.52 M | ||||
| Shares Outstanding | 10.94 M | ||||
| Shares Owned By Insiders | 4.70 % | ||||
| Shares Owned By Institutions | 51.86 % | ||||
| Number Of Shares Shorted | 49.83 K | ||||
| Price To Earning | (2.21) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.